4-[(2-nitro-benzenesulfonylamino)-methyl]-benzoic acid tert-butyl ester | 515171-00-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(2-nitro-benzenesulfonylamino)-methyl]-benzoic acid tert-butyl ester
• 英文别名: tert-butyl 4-[[(2-nitrophenyl)sulfonylamino]methyl]benzoate
• CAS: 515171-00-3
• 化学式: C₁₈H₂₀N₂O₆S
• 分子量: 392.433
• InChiKey: NHKQMQSBPGLDIE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  4-[(2-nitro-benzenesulfonylamino)-methyl]-benzoic acid tert-butyl ester 在 三乙酰氧基硼氢化钠 、 potassium carbonate 、 苯硫酚 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三苯基膦 、 三氟乙酸 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 43.0h， 生成 4-(((4-fluorobenzyl)(pyridin-3-ylmethyl)amino)methyl)-N-((S)-5-(3-(mesitylsulfonyl)guanidino)-1-(((R)-1-(naphthalen-1-yl)ethyl)amino)-1-oxopentan-2-yl)benzamide
  参考文献：
  名称：

  Pharmacophore-based small molecule CXCR4 ligands

  摘要：

  Low molecular weight CXCR4 ligands were developed based on the peptide T140, which has previously been identified as a potent CXCR4 antagonist. Some compounds with naphthyl, fluorobenzyl and pyridyl moieties as pharmacophore groups in the molecule showed significant CXCR4-binding activity and anti-HIV activity. Structure-activity relationships were studied and characteristics of each of these three moieties necessary for CXCR4 binding were defined. In this way, CXCR4 ligands with two types of recognition modes for CXCR4 have been found. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.032
• 作为产物：
  描述：

  4-氨甲基苯甲酸 在 硫酸 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 4-[(2-nitro-benzenesulfonylamino)-methyl]-benzoic acid tert-butyl ester
  参考文献：
  名称：

  Pharmacophore-based small molecule CXCR4 ligands

  摘要：

  Low molecular weight CXCR4 ligands were developed based on the peptide T140, which has previously been identified as a potent CXCR4 antagonist. Some compounds with naphthyl, fluorobenzyl and pyridyl moieties as pharmacophore groups in the molecule showed significant CXCR4-binding activity and anti-HIV activity. Structure-activity relationships were studied and characteristics of each of these three moieties necessary for CXCR4 binding were defined. In this way, CXCR4 ligands with two types of recognition modes for CXCR4 have been found. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.032

文献信息

• Alkyne matrix metalloproteinase inhibitors
  申请人：——

  公开号：US20030144274A1

  公开（公告）日：2003-07-31

  A compound of Formula I 1 or a pharmaceutically acceptable salt thereof, or a tautomer thereof, wherein G 1 , G 2 , and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseases mediated by MMP-13, including cancer and arthritis.

  Formula I1的化合物或其药用可接受的盐，或其互变异构体，其中G1、G2和B如申请中所定义，是MMP-13的选择性抑制剂。这些化合物可用于治疗由MMP-13介导的疾病，包括癌症和关节炎。
• Phenylene alkyne matrix metalloproteinase inhibitors
  申请人：Bunker Amy Mae

  公开号：US06849648B2

  公开（公告）日：2005-02-01

  A compound of Formula I or a pharmaceutically acceptable salt thereof, or a tautomer thereof, wherein G 1 , G 2 , and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseases mediated by MMP-13, including cancer and arthritis.

  公式I的化合物或其药学上可接受的盐，或其互变异构体，其中G1，G2和B如申请中所定义，是MMP-13的选择性抑制剂。这些化合物适用于治疗由MMP-13介导的疾病，包括癌症和关节炎。
• ALKYNE MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Warner-Lambert Company LLC

  公开号：EP1434585A1

  公开（公告）日：2004-07-07
• US6849648B2
  申请人：——

  公开号：US6849648B2

  公开（公告）日：2005-02-01
• [EN] ALKYNE MATRIX METALLOPROTEINASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEINASE MATRICIELLE (MMP) A BASE D'ALKYNE
  申请人：WARNER LAMBERT CO

  公开号：WO2003032999A1

  公开（公告）日：2003-04-24

  A compound of Formula (I) or a pharmaceutical acceptable salt thereof, or a tautomer thereof, wherein G1, G2, and B are as defined in the application, are selective inhibitors of MMP-13. The compounds are useful for treating diseases mediated by MMP-13, including cancer and arthritis.